Head and Neck Clinical Trial
Official title:
A Multicenter Phase II Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer
NCT number | NCT01693718 |
Other study ID # | 12141B |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | March 2003 |
Est. completion date | September 2004 |
Verified date | January 2024 |
Source | University of Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of the study is to test a particular combination of drugs and determine their ability to completely eliminate head and neck cancer.
Status | Completed |
Enrollment | 44 |
Est. completion date | September 2004 |
Est. primary completion date | September 2003 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 59 Years and older |
Eligibility | Eligibility Criteria: 1. Patients with Stage IV carcinoma of the nasal or oral cavity, nasopharynx pharynx, larynx, paranasal sinuses, cervical esophagus, or hypopharynx are eligible. Patients with Stage III carcinoma of the nasopharynx, base of tongue and hypopharynx are also eligible. Therapy is given with curative intent. Prior to entry in the study the resectability and standard treatment options for each patient will be determined during a joint evaluation by a team composed of an attending surgeon, a radiation oncologist and a medical oncologist. In addition the timing and feasibility of surgery will be determined in each patient prior to initiation of therapy. The unequivocal demonstration of distant metastasis confers in eligibility. 2. Measurable disease is not required, but all disease will be carefully evaluated. 3. Patients must have a histologically or cytologically confirmed diagnosis of squamous cell carcinoma or lymphoepithelioma. 4. Patients must have not received prior chemotherapy or radiotherapy. 5. Patients must have performance status of >60% 6. Patients must have a WBC count of >3.5, an ANC count >1500 and a platlet count of >100,000. 7. The serum creatinine must be equal to or less than 1.5 m/dlor the calculated creatinine clearance must exceed 50cc/min. 8. Patient must be free of significant infection or other severe complicating medical illness. 9. Pregnancy will constitute an absolute contraindication to entrance on this protocol. Females of child-bearing age should be using adequate contraception. |
Country | Name | City | State |
---|---|---|---|
United States | The University of Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response Rates | To evaluate the activity of 5 cycles of C-FHX/G-CSF in previously untreated patients with stage II and IV locoregionally advanced head and neck cancer. | 2-5 years | |
Secondary | Feasibility of administering adjuvant CRA and interferon alfa2a | To determine the feasibility of administering adjuvant CRA and interferon alfa2a for up to one or until tumor progression in patients completing local therapy. | 2-5 years | |
Secondary | Side effects of study regimen | To determine the pattern and degree of clinical toxicity of this regimen | 2-5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00661427 -
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
|
Phase 2 | |
Completed |
NCT03268993 -
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
|
N/A | |
Recruiting |
NCT00733434 -
The Use of Prostaglandin E1 in Head and Neck Microsurgery
|
Phase 4 | |
Recruiting |
NCT03053310 -
Value of Geriatric Screening to Predict Postoperative Morbidity for Head and Neck Cancer
|